-
公开(公告)号：US10590183B2
公开(公告)日：2020-03-17
申请号：US16382620
申请日：2019-04-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Glen Eugene Mikesell , Han Chang , Robert James Peach
IPC: C07K14/705 , A61K38/16 , C07K16/28 , C07K19/00 , A61K38/17 , A61K39/395 , G01N33/50 , A61K38/00 , A61K39/00
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
-
公开(公告)号：US09399052B2
公开(公告)日：2016-07-26
申请号：US14177641
申请日：2014-02-11
Applicant: Bristol-Myers Squibb Company
Inventor： Glen Eugene Mikesell , Henry Shen , Han Chang , Joshua N. Finger , Guchen Yang , Robert James Peach
IPC: C07H21/04 , C07K14/705 , A61K38/17 , C07K16/28 , C07K19/00 , A61K39/395 , A61K38/00 , A61K39/00
CPC classification number: C07K14/70532 , A61K38/00 , A61K38/1774 , A61K39/39533 , A61K2039/505 , C07K16/2827 , C07K19/00 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/10 , C07K2319/30 , C07K2319/40 , G01N33/5005 , Y02A50/396
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
Abstract translation: 本发明提供编码调节免疫或炎症反应细胞如T细胞的活化的B7相关因子的核酸。 还提供了包含编码B7相关多肽（包括BSL1，BSL2和BSL3）的核酸的表达载体和融合构建体。 本发明进一步提供分离的B7相关多肽，分离的包含B7相关多肽的融合蛋白，以及与B7相关多肽特异性反应的抗体或其部分。 此外，本发明提供利用B7相关核酸，多肽或肽的测定法。 本发明还提供可用于人或动物受试者的免疫调节的B7相关核酸，多肽，融合蛋白或抗体的组合物。
-
13.发明申请公开(公告)号：US20140154260A1
公开(公告)日：2014-06-05
申请号：US14177641
申请日：2014-02-11
Applicant: Bristol-Myers Squibb Company
Inventor： Glen Eugene MIKESELL , Henry Shen , Han Chang , Joshua N. Finger , Guchen Yang , Robert James Peach
IPC: C07K14/705 , A61K38/17 , C07K16/28 , A61K39/395
CPC classification number: C07K14/70532 , A61K38/00 , A61K38/1774 , A61K39/39533 , A61K2039/505 , C07K16/2827 , C07K19/00 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/10 , C07K2319/30 , C07K2319/40 , G01N33/5005 , Y02A50/396
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
Abstract translation: 本发明提供编码调节免疫或炎性反应细胞如T细胞活化的B7相关因子的核酸。 还提供了包含编码B7相关多肽（包括BSL1，BSL2和BSL3）的核酸的表达载体和融合构建体。 本发明进一步提供分离的B7相关多肽，分离的包含B7相关多肽的融合蛋白，以及与B7相关多肽特异性反应的抗体或其部分。 此外，本发明提供利用B7相关核酸，多肽或肽的测定法。 本发明还提供可用于人或动物受试者的免疫调节的B7相关核酸，多肽，融合蛋白或抗体的组合物。
-
公开(公告)号：US11919957B2
公开(公告)日：2024-03-05
申请号：US18047216
申请日：2022-10-17
Applicant: Bristol-Myers Squibb Company
Inventor： Prabhu Seshaiyer Bhagavatheeswaran , Nicholas Allan John Botwood , Han Chang , William J. Geese , Sabine Maier , Giovanni Selvaggi , Joseph Daniel Szustakowski
IPC: C12Q1/6886 , C07K16/28 , A61K39/00
CPC classification number: C07K16/2818 , C12Q1/6886 , A61K2039/545 , C07K2317/76 , C12Q2600/106 , C12Q2600/156
Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.
-
Patent Agency Ranking
公开(公告)号：US10683357B2
公开(公告)日：2020-06-16
申请号：US15474731
申请日：2017-03-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zhehong Cai , Indrani Chakraborty , Marie-Michelle Navarro Garcia , Thomas D. Kempe , Alan J. Korman , Alexander T. Kozhich , Hadia Lemar , Mark Maurer , Christina Maria Milburn , Michael Quigley , Xiang Shao , Mohan Srinivasan , Kent Thudium , Susan Chien-Szu Wong , Jochem Gokemeijer , Xi-Tao Wang , Han Chang , Patrick Guirnalda
IPC: C07H21/04 , C12P21/06 , C12N15/87 , C12N1/20 , C12N5/20 , C12N15/00 , C07K16/28 , C07K16/30 , A61P35/00 , A61K39/395 , G01N33/574 , A61K39/00
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US10400023B2
公开(公告)日：2019-09-03
申请号：US15229582
申请日：2016-08-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Glen Eugene Mikesell , Han Chang , Robert James Peach
IPC: C07K16/28 , C07K14/705 , A61K38/00
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
-
公开(公告)号：US20170190759A1
公开(公告)日：2017-07-06
申请号：US15218699
申请日：2016-07-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Glen Eugene MIKESELL , Han Chang , Robert James Peach
IPC: C07K14/705 , G01N33/50 , C07K16/28
CPC classification number: C07K14/70532 , A61K38/00 , A61K38/1774 , A61K39/39533 , A61K2039/505 , C07K16/2827 , C07K19/00 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/10 , C07K2319/30 , C07K2319/40 , G01N33/5005 , Y02A50/396
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
-
18.发明申请METHODS FOR SELECTING AND TREATING CANCER IN PATIENTS WITH IGF-1R/IR INHIBITORS 审中-公开用IGF-1R / IR抑制剂选择和治疗癌症患者的方法公开(公告)号：US20140309229A1
公开(公告)日：2014-10-16
申请号：US14351213
申请日：2012-10-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Fei Huang , Han Chang , Joan M. Carboni
CPC classification number: C12Q1/6881 , A61K31/53 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158
Abstract: The present invention relates generally to the field of pharmacogenomics, and more specifically to methods and procedures to determine drug sensitivity in patients to allow the identification of individualized genetic profiles which will aid in selecting cancer patients that are responsive to IGF-1R/IR inhibition.
Abstract translation: 本发明一般涉及药物基因组学领域，更具体地涉及确定患者药物敏感性的方法和程序，以允许鉴定将有助于选择对IGF-1R / IR抑制作用有反应的癌症患者的个体化遗传图谱。
-
公开(公告)号：US08674076B2
公开(公告)日：2014-03-18
申请号：US13711855
申请日：2012-12-12
Applicant: Bristol-Myers Squibb Company
Inventor： Glen Eugene Mikesell , Han Chang , Robert James Peach
CPC classification number: C07K14/70532 , A61K38/00 , A61K38/1774 , A61K39/39533 , A61K2039/505 , C07K16/2827 , C07K19/00 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/10 , C07K2319/30 , C07K2319/40 , G01N33/5005 , Y02A50/396
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
Abstract translation: 本发明提供编码调节免疫或炎性反应细胞如T细胞活化的B7相关因子的核酸。 还提供了包含编码B7相关多肽（包括BSL1，BSL2和BSL3）的核酸的表达载体和融合构建体。 本发明进一步提供分离的B7相关多肽，分离的包含B7相关多肽的融合蛋白，以及与B7相关多肽特异性反应的抗体或其部分。 此外，本发明提供利用B7相关核酸，多肽或肽的测定法。 本发明还提供可用于人或动物受试者的免疫调节的B7相关核酸，多肽，融合蛋白或抗体的组合物。
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.041 seconds)
